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Abbreviations
Alanine aminotransferase

ALT

Alpha glucosidase inhibitors

AGIs

Aspartate aminotransferase

AST

Diabetes mellitus

DM

Dipeptidyl peptidase-4

DPP-4

1,1-Diphenyl-2-picryl-hydrazyl

DPPH

Glucagon-like peptide-1

GLP-1

Middle East and North Africa:

MENA

p-nitro phenyl α-D-glucopyranoside

pNPG

Traditional Medicine

TM

*Dedicated to Professor Dr. Max Wichtl in recognition of his outstanding contribution to
pharmacognosy research.
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Abstract
Diabetes mellitus is a chronic disease and one of the most important public health challenges
facing mankind. Fagonia cretica L. (Zygophyllaceae) is a medicinal plant used widely in the
Punjab in Pakistan. A recent survey has demonstrated that traditional healers and herbalists
frequently use this plant to treat diabetes. In the current study, the traditional medicine was
prepared as a tea and the profile of the main metabolites present in the traditional medicine was
analysed via LC/MS/MS. The extract was shown to contain a number of phenolic glycosides
including

quercetin-3-O-rutinoside,

kaempferol-3(6’-malonylglucoside),

kaempferol-3-O-rutinoside,
isorhamnetin-3-O-rutinoside,

kaempferol-3-O-glycoside,
and

isorhamnetin-3-(6’’-

malonylglucoside) in addition to unidentified sulphonated saponins. The traditional medicine
inhibits α-glucosidase in vitro with an IC50 of 4.62 µg/ml. The hypoglycaemic effect of the
traditional medicine was evaluated in normoglycaemic and streptozotocin-treated diabetic rats,
using glibenclamide as internal control. The preparation (250 or 500 mg/kg body weight) was
administered once a day for 21 consecutive days. The dose of 500 mg/kg was effective in the
management of the disease, causing a 45% decrease in plasma glucose level at the end of the
experimental

period.

Histological

analysis

of

pancreatic

sections

confirmed

that

streptozotocin/nictotinamide treatment caused destruction of pancreatic islet cells, while
pancreatic sections from treatment groups showed that both the extract and glibenclamide
partially prevented this deterioration. The mechanism of this protective effect is not clear.
However, such a finding suggests that ingestion of the tea could confer additional benefits and
should be investigated further.
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Introduction
DM is a metabolic disorder caused by either an absolute or relative lack of insulin activity and is
characterised by an increased level of blood glucose leading to thirst and diuresis [1]. Further, it
is associated with long term micro vascular and macro vascular complications, such as diabetic
retinopathy, neuropathy, nephropathy and many others [2]. The rate of occurrence of DM is
escalating and has more than doubled globally since the early 1990’s with a 35.4 million people
suffering from the disease in the MENA region of which Pakistan contributes 7.02 million
diabetics [3]. The predicted increase in numbers of sufferers is 51.4% in Pakistan compared with
a regional increase of 39.2% over a single generation gap. This imposed a financial burden of
USD. 17.1 billion spent on the management of diabetes in the region during 2015 [4]. Lifestyle
changes for the management of type 2 DM include diet and exercise while groups including the
AACE, the Dutch College of General Practitioners and the IDF advocate AGI’s as first line
therapy for its treatment [5,6,7]. AGIs act by inhibition of alpha glucosidase enzymes and
fermentation of colonic starch and specifically target the postprandial hyperglycaemia [8, 9].
New classes of anti-diabetic drugs such as DPP-4 inhibitors, GLP-1 analogues and combined
receptor type 1 antagonists have been introduced in recent years. Studies have shown that the
combined administration of AGIs and DPP-4 inhibitors result in significant decrease in plasma
glucose fluctuations and are effective in reducing post prandial glycaemic excursions [10, 11].
Other therapies for diabetes include the drugs that act as secretagogues or sensitisers of beta cells
or by the inhibition of gluconeogenesis [12].
Over 70% of the population in countries like Pakistan still depend on TM options (Unani,
Ayurvedic) for their primary care [13], particularly in rural areas. This is due to a number of
factors such as inadequate or limited access to the modern medical systems and affordability. In
addition Unani, Ayurveda, and homeopathy have been accepted and integrated into the national
health system in Pakistan and are widely used throughout the country. There are approximately
52,600 registered Unani medical practitioners that serve the nation through both the public and
private sectors in urban and rural areas [13, 14]. An extensive survey among traditional healers
and herbalists in in the city of Bahawalpur and the Cholistan Desert in Pakistan was carried out
comprising of 99 informants during 2011 and 2012. This study collected data relating to the use
of medicinal flora for the treatment of diabetes [15]. The traditional healers and herbalists in this
study claimed to diagnose DM in their patients by observing symptoms such as weight loss,
4

fatigue, excessive urination and the presence of sugar in the urine. Fagonia Cretica L. (family
Zygophyllaceae) was frequently mentioned and highly recommended by both the traditional
healers and rural dwellers.
The genus Fagonia is composed of circa 35 different species, which are distributed across
tropical, subtropical and arid areas of the world and on all continents except Australia [16].
Several Fagonia species feature in Asian TM systems including Ayurveda and Unani [17, 18]. F.
cretica L. is found in North Africa, Spain, Cyprus, Turkey, and Saudi Arabia and throughout the
desert regions of western India and Pakistan [16]. A wide range of therapeutic uses have been
recently reviewed for F. cretica L., including anti-tumor, anti-inflammatory and neuroprotective
have recently been reviewed [17]. There only reports for the traditional use of F. cretica L. in the
treatment of diabetes cite its use as part of a multi-herbal mixture, where it is used in equal
quantities with aerial parts of Aloe vera and F. Tylophorahirsuta L. combined as an aqueous
extract [19, 20].
Crude phytochemical extracts and isolated compounds from F. cretica L. have been shown to
have a diverse range of biological activities including amongst others anti-haemorrhagic, antitumor, anti-inflammatory and neuroprotective cytotoxic anti-inflammatory and neuroprotective
[21, 22, 23, 24]. Active metabolites including the anti-inflammatory and anti-tumour triterpenes
taraxerol and ursolic acid [25, 26], and triterpenoid saponins with hederagenin and ursolic acid
and oleanoic acid aglycones have been isolated and the general presence of flavonoids has been
demonstrated [27, 28, 29]. In 2012, Lam et al. [30] demonstrated that an aqueous extract of F.
cretica L. induces DNA damage, cell arrest and apoptosis in MCF-7 (WT-p53) and MDA-MB231 (mutant –p53) breast cancer cells. However, despite the interesting results presented in this
study, there is no chemical fingerprint or characterisation of the extract investigated. More
recently Saleem et al. [31] isolated quinovic acid, quinovic acid-3β-O-β-d-glycopyranoside,
quinovic acid-3β-O-β-d-glucopyranosyl-(28→1)-β-d-glucopyranosyl ester from F. cretica L. and
have identified them as potential as potential DPP-4 inhibitors which might have use in the
treatment of diabetes and may explain in part the reported use of the TM in the treatment of DM.
Despite the body of phytochemical information that exists around F. cretica L. and the
well acknowledged differences in metabolomic composition of herbal materials that can be
caused by cultivation, environment and other factors [32, 33] no study to date using this TM has
5

reported on the metabolomics profile. In this study, the chemical fingerprint for the TM of F.
cretica L. has been generated by LC/MS/MS, and this profile directly corresponds to the TM
which shows positive effects in in vivo and in vitro models of diabetes.

Materials and Methods

Chemicals
Streptozotocin (purity ≥ 95% by HPLC) was purchased from Calibiochem® (EMD Chemicals,
San Diego, CA, USA), Nicotinamide (purity ≥ 99% by HPLC) was purchased from Acer
Scientific (USA) and Glibenclamide (purity ≥ 99% by HPLC) and D-glucose from Sigma (St.
Louis, MO, USA). HbA1c, creatinine, urea, ALT and AST test kits were purchased from Merck
(Pakistan). All other chemicals and reagents used were of analytical grade.

Plant Materials
The fresh aerial parts of the Fagonia Cretica L. (Zygophyllaceae) were collected after monsoon
during the month of May in 2012 from an area of abundant plant growth named Laatan Shinghar
in the Cholistan Desert, district Bahawalpur, Punjab, Pakistan. The taxonomic identification of
the plant was carried out by Prof. Dr. Muhammad Arshad Choudhary (Late), Director, Cholistan
Institute of Desert Studies (CIDS), Islamia University of Bahawalpur (IUB) and Pakistan. The
voucher specimens (3401/CIDS/IUB) for the plant were prepared and deposited at the herbarium
of CIDS, IUB.

Preparation of the Extract
Fresh plant material (2.0 Kg) was washed with tap water to remove the dust and other foreign
particles and dried under shade. The dried plant material was chopped into small pieces (1x1 cm
approx.) and extracted with boiling water (2 L) overnight as practiced by the local informants.
The aqueous extract was cooled and lyophilized. The percent yield of the lyophilized powder
was 10.15% of the dry plant material.
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LC-MS/MS analysis
Chromatographic separations were performed on a Dionex Ultimate 3000 RS liquid
chromatography system on a Dionex Acclaim RSLC 120 C18 column (2.1 × 100 mm, 2.2 μm)
with a binary gradient (A: water with 0.1% formic acid; B: acetonitrile with 0.1% formic acid) at
0.8 mL/min: 0 to 9.5 min, linear from 5% B to 100% B; 9.5 to 12.5 min, isocratic 100% B; 12.5
to 12.6 min, linear from 100% B to 5% B; 12.6 to 15 min, isocratic 5% B. The injection volume
was 2 μL.
Samples were analysed by as described in Sendker et al. [34] with the following
modifications: MS frequency was increased to 4 Hz; AutoMS2-mode was activated to target
each Full-scan-mass-spectrum's three most abundant ions of m/z 200-1000 and minimum
intensity of 2000 counts for up to two MS/MS experiments with the following setting: 624
summations with 80 eV collision energy and 130 Vpp collision RF + 313 summations with 16
eV and 130 Vpp + 313 summations with 16 eV and 300 Vpp were merged to one MS/MS
spectrum. An ion that had been chosen twice as precursor ion was excluded from further MS/MS
experiments for one typical chromatographic peak-base-width of 0.1 min. Full-scan MS- and
MS/MS spectra were typically extracted from the mass-calibrated raw data by using the Dissect
Compounds function of Compass Data Analysis 4.1 SR1. Spectra of the three most abundant
residual chromatographic peaks (compounds 8-10) were extracted by integrating the
corresponding time-ranges from a base peak chromatogram (mass range m/z 200-1000). Product
ions were obtained from MS/MS experiments of protonated molecules or ammonium adduct
ions, or from the Full-scan mass-spectra if no suitable MS/MS experiment was triggered. UV
spectra were extracted by integrating the corresponding peaks from UV chromatograms at λ =
230 nm or λ = 280 nm. All UV spectra and the Full-scan mass spectra of compounds 8-10 were
corrected by subtracting from them the respective data of the respective peak borders. All other
Full-scan mass spectra were corrected during the Dissect-Compounds-Processing by excluding
any mass signal with deviating elution profile. Molecular formulas were determined using the
Smart Formula tool of Data Analysis 4.1 SR1 under consideration of UV spectra and
unambiguously determined ion formulas of smaller product ions.
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Animals
Ethical approval for the animal studies was obtained from the Animal Use Committee of the
International Centre for Chemical and Biological Sciences (ICCBS), University of Karachi,
Pakistan. In-house bred healthy adult female Wistar rats weighing 180-220 g (ICCBS) were
utilised throughout the experiment. Animals were housed in standard environmental conditions
of temperature, humidity, and light: dark cycle in clean polypropylene cages lined with husk bed
and were fed on standard rodent diet with free access to water throughout the period of study.
In Vitro Studies Enzyme Inhibition Studies: α – Glucosidase inhibition assay
To determine the enzyme inhibition activity of the compound, the enzyme (α-glucosidase) from
yeast (Saccharomyces cerevisiae) and the substrate (pNPG) was purchased from Sigma Aldrich,
USA. The standard enzyme inhibition protocol used in the Enzyme Inhibition Laboratory of the
Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad,
Pakistan, was adopted with some modifications [35]. The assay was performed using 96-well
plates. Solutions of the inhibitor (in methanol) and that of the enzyme and the substrate (in 0.07
M phosphate buffer, pH 6.8) were prepared using the standard procedures described for the
assay. The enzyme (2.5 UmL-1) and the test compound (10 µL each) were pre-incubated at 37°C
for 30 min before the addition of the substrate (10 µL) to each well of 96-well plate. The reaction
mixture was incubated at 37°C for 30 min and stopped by adding 80 µL of 0.2 M Na2CO3.
Acarbose and methanol were used as positive and negative control, respectively. The inhibitory
activity of the compound was determined by measuring the p-nitro phenol released from pNPG
at 405 nm using spectrophotometer (BioTek ELx800). The % inhibition was calculated by
following equation:

IC50 value (Concentration of the inhibitor that inhibited 50% of α-glucosidase activity)
was calculated using non-linear curve fitting program GraphPad PRISM 5.0 (San Diego,
California, USA).
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In Vivo animal Studies - Acute Oral Toxicity Evaluation
The F. cretica L. extract was evaluated for acute oral toxicity in rats. A single oral administration
of the extract at different doses (500 and 1000 mg/kg body weight), was given to two different
groups consisting of five Wistar rats. The animals were observed for behavioural and toxic
(mortality) effects continuously at short intervals of time, initially for 24 h, and then again at 48
and 72 h, following extract administration. Serum biochemical parameters were also evaluated to
check the toxicity to kidney and liver.

Evaluation of Extract in Normal Healthy Rats
Serum glucose levels of the animals were checked (after an overnight fasting period of 12–14 h,)
by collecting the blood by snipping the tail vein using a glucometer Accu-Chek® (Roche
Diagnostics, Mannheim, Germany). The animals were then divided into two groups (n =
5/group). Group 1 served as the control, while group 2 was given a single oral dose of 500 mg/kg
of the extract. Serum glucose levels of the animals were checked at 0, 1, 2, and 3 h. The values
are expressed as mean ± SEM and p-value was calculated.

Induction of Diabetes
Rats were fasted for 12-14 h before the induction of the experimental diabetes. Non-insulin
dependent diabetes mellitus (NIDDM) (Type II) was induced in rats by a single iv. injection of
60 mg/kg of Streptozotocin, freshly prepared in cold citrate buffer (0.1 M, pH 4.5) followed after
15 min by 120 mg/kg of freshly dissolved Nicotinamide in normal saline, injected
intraperitoneally. Control rats were injected with an equivalent volume of citrate buffer only.
Rats were given the glucose solution (5%) for 24 h. Diabetes was confirmed by the elevated
levels of serum glucose after 72 h and then on day 7 by collecting fasting blood by snipping the
tail vein, and serum glucose was determined by glucose oxidase-peroxidase (GOD-POD)
method. Only those rats that have fasting blood glucose above 250 mg/dl were selected and used
for the study.

Study Design and Evaluation of TM in Experimental Animals
Once the diabetes was confirmed the animals were divided randomly into five groups consisting
of five animals each (n = 5) as follows:
9

Group I: Non-diabetic control rats
Group II: Untreated diabetic control rats
Group III: Diabetic rats treated with F. cretica 250 mg/kg of body weight
Group IV: Diabetic rats treated with F. cretica 500 mg/kg of body weight
Group V: Diabetic rats treated with glibenclamide
Group III and IV were given their respective treatments after one week of induction of
diabetes. The first day of treatment was considered as Day 0. The treatment was continued till
day 21. Freshly prepared solutions of extracts in distilled water (5 mL) were fed orally to the rats
at a dose of 250 mg/kg and 500 mg/kg body weight, once a day for 21 days to group III and IV,
respectively. Group I and II were given water only in place of extract, while group V was treated
with the standard drug Glibenclamide (5 mg/kg).
Body weights and serum sugar levels were determined weekly after an overnight fasting
of 12-14 h. On day 22, the animals were anaesthetised after an overnight fasting using sodium
pentothal (60 mg/kg), sacrificed, and their blood and organs were collected for further
biochemical and histopathological examinations, respectively.

Histopathological Studies
Organs (Pancreases and Kidneys) were removed after dissection and placed in neutral buffered
formalin (NBF, 10%) for fixation. Then, they were washed repeatedly with distilled water,
dehydrated with increasing concentrations of 2- propanol, and embedded in paraffin. Sections (5
μm thick) were made using microtome blades. The sections were deparaffinised, rehydrated with
decreasing concentrations of 2-propanol, and mounted on glass slides. The slides were stained
with haematoxylin and eosin, double blinded, and analysed.

Statistical Analysis
Data are expressed as the mean ± SEM. Statistical analyses were performed by using the
Statistical Package for Social Science version 15.0 (SPSS) and GraphPad PRISM 5.0. Analysis
of Variance (ANOVA) followed by unpaired and paired t-tests (2-tailed) were performed to
detect any significant differences of means between and within group. Differences were
considered as statistically significant for p-values less than or equal to 0.05 (p ≤ 0.05).
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Results and Discussion
The TM sample was prepared as a tea using freshly dried aerial parts as described by traditional
healers [15]. The powder was lyophilised and was analysed using a modification of the methods
described by Sendker et al. [34]. The corresponding LC/MS chromatographic fingerprint shows
the main components of the extract (Fig. S1, Supporting Information). High-resolution MS and
MS/MS spectra of these peaks were obtained from a representative LC-MS data set that was
analysed using the Dissect Compounds algorithm of Data Analysis 4.0 (Bruker Daltonics). The
algorithm detected 26 compounds. Expansions (Fig. 1), are focused on relevant peaks. The main
peaks were tentatively characterised and correspond to glycosides of quercetin, kaempferol and
isorhamnetin (Table 1 and Table S1, Supporting Information). The major compounds and their
fragmentation patterns are shown in Fig. 2. Such glycosides have previously been detected in
other Fagonia species [16, 29]. An unidentified iridoid-like compound (Fig. 1; peak 9; Fig. S2,
Supporting Information) together with two sulphonated triterpenoid saponins (Fig. 1; peaks 17
and 18; Fig. S3, Supporting Information) have been detected, and although not fully
characterised, they are reported in this TM for the first time. Sulphonated saponins of the ursolic
acid aglycone have been isolated from related species F. indica [35].

Fig. 1. LC/MS profile of F. cretica TM focused on relevant peaks., The dark line represents a
base peak chromatogram of m/z 200-1000. Peaks 8, 9, and 10 have been detected from the BPCplot, the others by using the Dissect-Compounds-Algorithm of Bruker Data Analysis 4.1.
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Table 1. The M/z’s for major compounds in the TM tea of F. cretica L by LC/MS in the positive ionisation mode. NI=Not identified,
NFI=Not fully identified.
Rt
(min)

Peak No

m/z

Adduct ion(s)

MS/MS Fragment ions (m/z)
(rel. Int. in percent)

Molecular
formula

Identity

1.278

7

257.0652

[M+H]+

MS1: 211.0600 (14), 193.0481
(10), 147.0429 (12), 119.0487
(7), 107.0489 (8)

C11H13O6

Piscidic acid

2.354

9

389.1078

[M+H]+

MS1: 371.0966 (17), 297.0534
(8), 265.1421 (20), 213.0763
[base peak]+

C16H21O10

Glycoside*. The
aglycone is C10H13O5,
m/z 213 Possible
iridoid glycoside.

3.371

11

611.1587

[M+H]+

MS1: 303.0561 (17)

C27H31O16

Quercetin-3-Orutinoside (Rutin)

3.603

12

595.1654

[M+H]+

MS2: 595.1642 (54), 449.1091
(41), 287.0567 (100)

C27H31O15

Keampferol-3-Orutinoside

3.656

13

625.1787

[M+H]+

MS2: 625.1828 (62), 479.1186
(32), 317.0683 (100);
285.0358 (13)

C28H33O16

Isorhamnetin-3-Orutinoside

3.722

14

449.1100

[M+H]+

MS2: 449.1201 (37), 287.0574
(100)

C21H21O11

Kaempferol-3glucoside

3.888

15

535.1096

[M+H]+

MS1: 287.0536 (9)

C24H23O14

Kaempferol-3(6’malonylglucoside)

3.964

16

565.1216

[M+H]+

MS1: 287.0506 (14)

C25H25O15

Isorhamnetin 3-(6''malonylglucoside

4.711

17

899.4061

[M+Na]+

MS1: 715.3730 (100),
635.4144 (14), 553.3210 (59)

C42H68NaO17S

NFI: Saponin
dihexoside of
C30H48O7S

4.895

18

985.4082

[M+Na]+

MS1: 801.3719 (100),
553.323215 (26)

C45H70NaO20S

NFI: Saponin
dihexoside, malonated
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Fig. 2. Fragmentation patterns for the most abundant flavonoid glycosides characterised by
LC/MS in the TM of F. cretica.
In an acute toxicity study, the TM of F. cretica did not show any abnormal behaviour, no
mortality was recorded up to the dose of 1,000 mg/kg body weight. Body weights and food
consumption were similar to that of the control group and no significant differences were seen.
No makers of toxicity were seen, which indicates that there were no gross pathological changes
or any toxic effect on chronic administration of the extract, reflecting a good safety profile at a
preliminary level. Thus, it can be concluded that F. cretica L. extract was safe at a dose of 1000
mg/kg. The observed safety profile of the TM (Table S2, Supporting Information) is in keeping
with its traditional use over long periods.
Free radicals can be damaging and lead to various chronic diseases such as diabetes,
arthritis, and asthma [37]. Using the DPPH radical assay, the free radical scavenging activity of
the F. cretica L. TM did not show any significant inhibition (33%) compared to the standard
control, Propyl gallate (90.01%). However the radical scavenging potential of phytochemically
13

derived ethyl acetate fraction of Fagonia Cretica L. is highly significant (93%). This reinforces
the differences that exist between crude fractions, isolates and the actual TM administered and
reinforces the need for studies that concentrate on the actual formulation of the herbal drug that
is administered as a medicine.
Competitive inhibition of the key hydrolysing enzymes of carbohydrate digestion (αglucosidase and α-amylase) present in the small intestine is an important approach for the
management of diabetes [38] and is especially suited for a traditional Pakistani carbohydrate rich
diet where carbohydrates contribute to over 60% of the usual Pakistani or South Asian diet [39].
The alpha glucosidase inhibitory effect of the TM was determined using α-glucosidase from
yeast (Saccharomyces cerevisiae) using the substrate pNPG and 96-well plates and standardised
protocols [35]. The standard α-glucosidase inhibitor acarbose was used as a control (Fig. 3).
The IC50 value for α – glucosidase inhibition of 4.62 µg/ml (95% confidence limits between
3.066 and 6.916 µg/ml) was obtained for the TM, while the IC50 value of acarbose was 17.4
µg/ml (95% confidence limits between 11.44 and 25.7 µg/ml). Thus, inhibitory activity of the
TM is comparable to that of the commercially available standard drug acarbose. Furthermore,
common side effects of acarbose might include abdominal distention and pain and diarrhea,
though such side effects are not associated with F. cretica as a TM [17].

Fig. 3. Effect of F. cretica and acarbose on α-glucosidase inhibitory activity assessed by
spectrophotometric measurement at 405 nm of p-nitro phenol released from pNPG by αglucosidase from S. cerevisiae. Values are expressed as the mean ± SEM, n=3.
14

In this study a graded dose response on serum glucose levels was observed in normal
healthy rats, when they were treated with the TM of F. cretica L. The dose-dependent
hypoglycemic effects of the TM extract were observed in animals treated with 250 mg/kg and
500 mg/kg of body weight, causing a 4.6% (p = 0.01) and 15.97% (p = 0.003) decrease in serum
glucose levels, respectively, after 3 h of treatment. Serum glucose levels were recorded for 3 h
and the results showed a gradual decrease in the plasma glucose levels when compared with the
normal untreated group (Fig. 4). Since F. cretica can reduce blood glucose levels in
normolgycaemic animals, there exists the possibility that high doses might precipitate a
hypoglycaemic crisis and potential coma. However, such an effect has not been reported as a
consequence of its use in TM [17]. The effects of the TM on repeated administration on a daily
basis in STZ-NIC-induced diabetic rats is shown in Fig. 5.

Fig. 4. Effects of F. cretica at 250 and 500 mg/kg on fasting blood glucose levels in female
Wistar normoglycemic rats. Values are expressed as the mean ± SEM, n=5.
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Fig. 5. Effects of F. cretica at 250 and 500 mg/kg and glibenclamide 5mg/kg on STZ/NIC
diabetic rats given 5% glucose solution for 24 h. Values are expressed as the mean ± SEM, n=5.
The blood glucose lowering effects of the plant extract were evaluated at two different
doses (250 mg/kg and 500 mg/kg). The effect was found to be dose dependent. Both of the doses
showed a fasting blood glucose lowering effect with a more pronounced and significant (p <
0.05) effects observed with 500 mg/kg (45% decrease) at the end of the experimental period on
day 21 when compared with that of the untreated diabetic group. The group treated with 250
mg/kg did not show any significant decrease in serum sugar levels of the rats, while
glibenclamide (GB) at a dose of 5mg/kg treated group reduced the serum glucose levels by
56.4%. Serum glucose levels of different treatment groups on day 0 and day 21 are compared in
Table 2. It should be noted that the blood glucose-lowering effect of the extracts in streptozocininduced diabetic rats was not a consequence of the alpha-glucosidase inhibitory activity, since
these rats were fed with 5% glucose solution. While the hypoglycaemic target in diabetic rats is
currently unknown, it is separate and distinct from the alpha-glucosidase inhibitory activity, and
both activities may be additive in the clinical setting.
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Table 2. Serum glucose levels of different treatment groups on day 0 and day 21. Effects of F.
cretica at 250 and 500 mg/kg and glibenclamide 5 mg/kg on STZ/NIC diabetic rats given 5%
glucose solution for 24 h. Values are expressed as the mean ± SEM, n=5. ***p<0.001.
Sr. No.

Fasting Serum Glucose mg/dl

Treatment Groups

Day 0

Day 21

1.

Normal Control (n=5)

88.00 ± 2.74

89.20 ± 1.20

2.

Untreated Diabetic (n=5)

294.00 ± 25.71

501.60 ± 9.10

3.

F.c. Treated 250 mg/kg (n=5)

246.00 ± 36.88

248.20 ± 21.58

4.

F.c. treated 500 mg/kg (n=5)

277.40 ± 32.80

152.40 ± 29.46***

5.

GB Treated (n=5)

281.00 ± 6.979

122.60 ± 4.49***

Fig. 6. Histology of Pancreas of different treatment groups: a. Pancreas of normal control. b.
Pancreas of untreated diabetic. c. Pancreas of F. cretica treated (500 mg/kg). d. Pancreas of F.
cretica treated (250 mg/kg). e. Pancreas of GB treated.
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The histological evaluation of the pancreatic tissue sections (H&E-stained) was evaluated
in different experimental rat groups (normal control, untreated diabetic, F. cretica L. 250 mg/kg
treated, F. cretica 500 mg/kg treated, and GB-treated) after 21 days of treatment. Pancreatic
tissue images from selected groups are shown in Fig. 6. In normal control rats the pancreatic
sections revealed that the islets of Langerhans were abundantly distributed having normal
cellular characteristics (moderate to large size, with well-formed, oval to round shape) and
diameter of pancreatic islets (Fig. 6a) when compared with other groups.
In contrast, the pancreatic islets of the untreated diabetic rats were less distributed with
irregular structure (reduced in size, neither round nor oval), (Fig. 6b). However, in the treated
group with F. cretica L. extract (500 mg/kg), a moderate distribution of pancreatic islets was
observed, and the islets appeared to have well-formed medium size with oval shape (Fig. 6c),
while the treatment with the extract (250mg) also appeared similar but less in size and number of
islet cells (Fig. 6d). The standard drug GB also restored such irregularity to the structure similar
to that of the normal control group and improved the islets size (Fig. 6e). The results showed that
the extracts were found to improve the pancreatic islets size, but the TM could not bring them to
normal as seen in control rats. The administration of the streptozotocin caused a partial structural
and dimensional damage to the islets of Langerhans, resulting in necrosis and infiltration of the
β-cells and inhibit insulin secretion causing a state of diabetes in experimental rats. Treatment
with positive control drug glibenclamide at the dose of 5 mg/kg reinstated the normal cellular
structure and size of islets. The pancreas histology of the group treated with F. cretica extract
(500 mg/kg) showed an improved architecture of the islets, greater persistence and lesser degree
of necrotic changes when compared with that of the untreated diabetic group.
Saleem at al. [31] have reported that extracts of F. Cretica act as DDP-4 inhibitors and
suggest that extracts should be investigated for a hypoglycaemic activity in vivo, since the gliptin
group of drugs, acting on DDP-4, are effective anti-diabetics. In the present work, we have
chemically fingerprinted and demonstrated, for the first time, a hypoglycaemic effect of a TM
made from F. cretica in normoglycaemic and streptozotocin-treated diabetic rats. Furthermore,
we have shown, in this study, that there are additional activities which may augment any DPP-4
inhibitory activity as previously described [31]. We have shown that the extracts composed of
phenolic glycosides inhibit α-glucosidase activity to the same degree as the anti-diabetic drug
acarbose. One of the components fingerprinted in the TM, quercetin-3-O-rutinoside (rutin), has
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been reported to act as an inhibitor of α-glycosidase [40] and to decrease plasma glucose levels
and increase insulin release in streptozotocin-treated rats [41]. Additionally, rutin increases
glucose uptake in hepatocytes in vitro and in mice in vivo, implying its potential role in insulin
resistance [42]. Quercetin, the aglycone of rutin, which may be a metabolite of the TM after
ingestion, is believed to influence glycemic control in its own right, via reduction of intestinal
glucose absorption and, probably, GLP-1 secretion [43].
In addition, routine histological analysis of pancreatic sections confirmed that
streptozotocin/nicotinamide treatment caused destruction of pancreatic islet cells. However, a
histological examination of pancreatic sections from treatment groups showed that both the
extract and Glibenclamide seemed to partially prevent this deterioration. This activity of
glibenclamide has been observed in a previous study [44]. The mechanism of this protective
effect is not clear; it may be limited to the processes involved in the mutagenic action of
streptozotocin and it is not known whether this activity of the extract confers any clinical
advantage. However, such a finding might suggest that it could confer additional benefits and
should be investigated further. We believe that the current study supports the use of the TM
prepared from F. cretica in the treatment of DM in Pakistan.
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